- Trials with a EudraCT protocol (65)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
65 result(s) found for: Disease Gene Identification.
Displaying page 1 of 4.
EudraCT Number: 2007-007276-41 | Sponsor Protocol Number: Ram_GEP_1 | Start Date*: 2008-05-13 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | ||
Full Title: Gene expression profiling in skeletal muscle of healthy subjects treated with ramipril | ||
Medical condition: healthy young males | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006381-29 | Sponsor Protocol Number: EXPRESSION | Start Date*: 2009-11-12 | ||||||||||||||||||||||||||
Sponsor Name:Universitätsmedizin Mainz | ||||||||||||||||||||||||||||
Full Title: Neoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene... | ||||||||||||||||||||||||||||
Medical condition: Eligible will be only females between 18 - 70 years of age, suffering from histologically confirmed primary breast cancer, nodal status positive or negative, phase cT2, cT3, or cT4 including inflam... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003895-65 | Sponsor Protocol Number: DAL-301 | Start Date*: 2016-06-22 | |||||||||||
Sponsor Name:DalCor Pharma UK Ltd, Leatherhead, Swiss Branch Zug | |||||||||||||
Full Title: A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Sy... | |||||||||||||
Medical condition: This study is investigating the cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in subjects wit... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) SE (Completed) SK (Completed) DK (Completed) FI (Completed) PT (Completed) DE (Completed) HU (Completed) ES (Ongoing) AT (Completed) CZ (Completed) BG (Completed) RO (Ongoing) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005096-42 | Sponsor Protocol Number: BO18279 | Start Date*: 2005-06-24 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A phase II marker identification trial for Tarceva in second line NSCLC patients | ||
Medical condition: Advanced (stage IIIb and IV) non small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) GB (Completed) EE (Completed) DE (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005702-22 | Sponsor Protocol Number: IELSG39 | Start Date*: 2013-03-17 |
Sponsor Name:INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP | ||
Full Title: International prospective Phase 2 trial addressing the efficacy of first-line Chlamydophila psittaci-eradicating therapy with protracted administration of doxycycline followed by eradication moni... | ||
Medical condition: Patients with newly diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001730-26 | Sponsor Protocol Number: 205756 | Start Date*: 2017-11-30 | |||||||||||
Sponsor Name:Orchard Therapeutics (Europe) Ltd | |||||||||||||
Full Title: A single arm, open label, clinical study of cryopreserved autologous CD34+ cells transduced with lentiviral vector containing human ARSA cDNA OTL-200, for the treatment of early onset Metachromatic... | |||||||||||||
Medical condition: Metachromatic Leukodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004874-42 | Sponsor Protocol Number: TRAFO001 | Start Date*: 2009-02-06 | |||||||||||
Sponsor Name:Institut für Frauengesundheit GmbH | |||||||||||||
Full Title: Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Offene, prospektive, multizentrische Phase IV-Studie zur Untersuchung des Einflusses von pharmakogenetischen M... | |||||||||||||
Medical condition: The study examines the influence of pharmacogenetic markers on the efficacy and side effects in postmenopausal, steroid hormone positive breast cancer patients, who are treated with Letrozol. The p... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002966-37 | Sponsor Protocol Number: 1-2018BSMO | Start Date*: 2019-01-23 |
Sponsor Name:Belgian Society of Medical Oncology | ||
Full Title: Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. | ||
Medical condition: Advanced cancer patients that have a germline mutation or a somatic mutation in their tumor. Prostate and ovarian cancer patients and breast cancer patients who carry a BRCA1/2 mutation will be exc... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-002566-35 | Sponsor Protocol Number: SL0007 | Start Date*: 2008-03-19 | |||||||||||
Sponsor Name:UCB Inc | |||||||||||||
Full Title: A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patien... | |||||||||||||
Medical condition: systemic lupus erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) LT (Completed) ES (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002636-82 | Sponsor Protocol Number: OTL-200-07 | Start Date*: 2019-12-02 | |||||||||||
Sponsor Name:Orchard Therapeutics (Europe) Limited | |||||||||||||
Full Title: An open label, non-randomised trial to evaluate the safety and efficacy of a single infusion of OTL-200 in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD) | |||||||||||||
Medical condition: Metachromatic Leukodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002209-20 | Sponsor Protocol Number: 2015/222/HP | Start Date*: 2017-10-05 |
Sponsor Name:CHU-Hôpitaux de Rouen | ||
Full Title: PRODIGE 50 - ASPIK : French prospective randomised double blind study on aspirin versus placebo in resected colon cancer with PI3K mutation stage III or II high risk | ||
Medical condition: Mutated PI3K colonic adenocarcinoma patients with surgical resection R0 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003975-23 | Sponsor Protocol Number: IGX1-ENT-XS-16-01 | Start Date*: 2020-04-20 | |||||||||||
Sponsor Name:Asherman Therapy S.L.U. | |||||||||||||
Full Title: Efficacy and safety of autologous, mobilized, non-expanded CD133+ cells to treat Asherman´s Syndrome: A prospective, multi-center, phase I/II clinical trial. | |||||||||||||
Medical condition: Asherman's syndrome also known as intrauterine synechiae | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003738-40 | Sponsor Protocol Number: BO21129 | Start Date*: 2008-08-07 | |||||||||||
Sponsor Name:ROCHE | |||||||||||||
Full Title: A phase II Biomarker Identification Trial for Erlotinib (Tarceva) in Patients with Advanced Pancreatic Carcinoma. | |||||||||||||
Medical condition: Advanced Pancreatic carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) LV (Completed) DE (Completed) LT (Completed) BG (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000589-31 | Sponsor Protocol Number: NEMESIS | Start Date*: 2018-02-02 | ||||||||||||||||
Sponsor Name:SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA | ||||||||||||||||||
Full Title: multi stage phase II trial of Nivolumab (an anti –PD-1) in patients with platinum resistant Mismatch Repair deficient germinal cells tumours | ||||||||||||||||||
Medical condition: patients with platinum resistant Mismatch Repair deficient germinal cells tumours | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000615-99 | Sponsor Protocol Number: 00465 | Start Date*: 2006-12-28 | |||||||||||
Sponsor Name:University Medical Center Freiburg | |||||||||||||
Full Title: Freiburger ZNS-NHL Studie Therapie für Patienten mit primären Non-Hodgkin Lymphomen des ZNS – Sequentielle Hochdosis-Chemotherapie mit autologer peripherer Blutstammzelltransplantation | |||||||||||||
Medical condition: primary Non-Hodgkin Lymphoma of the Central Nervous System (PCNSL), histologically confirmed Age: 18 - 65 years | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002806-28 | Sponsor Protocol Number: SOLTI-1502 | Start Date*: 2019-10-25 |
Sponsor Name:SOLTI | ||
Full Title: TARGETING THE PAM50 HER2-ENRICHED PHENOTYPE WITH ENZALUTAMIDE IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER | ||
Medical condition: Male or pre/post-menopausal women age ≥ 18 years with advanced HR+/HER2-negative locally advanced/metastatic breast cancer resistant to endocrine therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002318-22 | Sponsor Protocol Number: CTBM100C2303 | Start Date*: 2009-09-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder from a ... | |||||||||||||
Medical condition: Pseudomonas aeruginosa infection in cystic fibrosis patients | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004507-36 | Sponsor Protocol Number: CTBM100DDE01 | Start Date*: 2008-08-19 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A multicenter, open label, 2 period cross-over study to evaluate the Pharmacokinetics of an 8 week continuous treatment with 1x300mg/d and 2x300mg/d TOBI® inhaled with the PARI eFlow® rapid in Cyst... | |||||||||||||
Medical condition: patients with cystic fibrosis and chronical infection with Pseudomonas aeruginosa | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001057-40 | Sponsor Protocol Number: 301OTC01 | Start Date*: 2017-03-14 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical, Inc. | |||||||||||||
Full Title: A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OT... | |||||||||||||
Medical condition: Ornithine transcarbamylase deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003369-85 | Sponsor Protocol Number: ID-069A301 | Start Date*: 2018-05-14 | |||||||||||
Sponsor Name:Idorsia Pharmaceuticals Ltd | |||||||||||||
Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) NL (Completed) BE (Completed) IE (Completed) ES (Ongoing) NO (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.